Institutional Fund
Acorn Capital Advisors, LLC
New York, NYCIK 20544108 filings on record
Portfolio Value
$351.84M
Q1 2026
Holdings
22
Reported positions
New Buys
2
Opened this quarter
QoQ Change
+19.2%
from $295.13M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Terns Pharmaceuticals Inc26.2%
- Cg Oncology Inc21.8%
- Urogen Pharma Ltd8.6%
- Puma Biotechnology Inc7.5%
- Trevi Therapeutics Inc7.3%
- Candel Therapeutics Inc4.9%
- Other23.8%
Portfolio Holdings
22 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Terns Pharmaceuticals Inc | 1.75M | $92.06M | 26.2% | 0 | Held |
| 2 | Cg Oncology Inc | 1.13M | $76.58M | 21.8% | −1.0K | Reduced |
| 3 | Urogen Pharma Ltd | 1.67M | $30.09M | 8.6% | +225.0K | Added |
| 4 | Puma Biotechnology Inc | 4.13M | $26.40M | 7.5% | 0 | Held |
| 5 | Trevi Therapeutics Inc | 2.14M | $25.59M | 7.3% | 0 | Held |
| 6 | Candel Therapeutics Inc | 3.50M | $17.21M | 4.9% | +917.4K | Added |
| 7 | Bicara Therapeutics Inc | 643.4K | $12.80M | 3.6% | 0 | Held |
| 8 | Onkure Therapeutics Inc | 2.84M | $11.76M | 3.3% | 0 | Held |
| 9 | Jade Biosciences Inc | 786.8K | $11.05M | 3.1% | +786.8K | New |
| 10 | Protara Therapeutics Inc | 1.75M | $9.13M | 2.6% | 0 | Held |
12 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio